Normal bile sterile; bacteria ascend from duodenum
E. coli, Klebsiella, Enterococcus most common
Increased CBD pressure promotes bacteremia
Suppurative cholangitis
Pus under pressure in CBD
Rapid systemic dissemination
Endotoxin-mediated organ dysfunction
Therapeutic Considerations
Evidence base for ERCP
ERCP with sphincterotomy and stone extraction
Standard definitive treatment for confirmed CBD stones
6 to 15% overall complication rate
Post-ERCP pancreatitis 4 to 10% — most common complication
Timing of ERCP in cholangitis
Early ERCP (< 24-48 hours) improves outcomes in Grade II
Urgent ERCP (< 12 hours) for Grade III cholangitis after stabilization
Delayed ERCP associated with increased mortality and organ failure
ERCP vs surgery for CBD clearance
Single-stage laparoscopic CBD exploration equivalent to two-stage ERCP-then-cholecystectomy
Shorter hospital stays with single-stage approach
Decreased morbidity compared to two-stage
Intraoperative cholangiography avoids unnecessary ERCP in intermediate-risk group
Spontaneous stone passage
Occurs in approximately 30 to 40% of patients before ERCP
More likely with small stones < 5 mm
Labs may normalize with spontaneous passage
Does not eliminate need for cholecystectomy
Post-cholecystectomy recurrence
ERCP alone without cholecystectomy: 9.2% recurrent biliary event readmission rate
vs 2.2% with same-admission cholecystectomy
Primary CBD stone recurrence after sphincterotomy
4 to 6% annual recurrence rate
Higher with dilated CBD, pigment stones, biliary stasis
NSAIDs in biliary colic and choledocholithiasis
NSAIDs superior to antispasmodics for pain relief
Cochrane review: NNT approximately 3 vs placebo
Non-inferior to opioids with fewer adverse effects
Mechanism: prostaglandin inhibition reduces sphincter of Oddi pressure
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for Choledocholithiasis
Diagnosis explanation
You have been diagnosed with choledocholithiasis — gallstones in your bile duct
Bile duct stones can cause pain, jaundice, and serious infection if not treated
Your bile duct has been cleared or you are being monitored for further treatment
Diet and activity
Low-fat diet until your surgery or specialist appointment
Avoid: fried foods, full-fat dairy, red meats, processed fats
Small frequent meals are better tolerated
Avoid rapid weight loss programs — they increase gallstone formation
Regular light activity is encouraged; avoid strenuous exercise if pain persists
Medications
Take all prescribed medications as directed
Complete any antibiotic course fully even if feeling better
Pain medication: take as prescribed and only as needed
Avoid NSAIDs if kidney function is reduced — ask your doctor
Follow-up instructions
Surgical follow-up within 1 to 2 weeks for cholecystectomy planning
If ERCP was performed: follow up with gastroenterologist within 1 week
Do not delay follow-up — ERCP alone without gallbladder removal has a 9% readmission risk
Return to emergency department immediately for
Fever or chills
Worsening abdominal pain not controlled by medication
New or worsening jaundice (yellowing of skin or eyes)
Dark urine or pale grey stools
Persistent vomiting preventing oral intake
Confusion, dizziness, or feeling faint
Signs of infection at any procedure site
Post-ERCP specific instructions
Mild sore throat and bloating are expected for 24 to 48 hours
Return immediately for severe abdominal pain after ERCP — may indicate pancreatitis or perforation
Avoid driving for 24 hours if sedation was used
References
Guidelines and key sources
ASGE Guideline on the Role of Endoscopy in the Evaluation and Management of Choledocholithiasis
Buxbaum JL, Abbas Fehmi SM, Sultan S, et al.
Gastrointestinal Endoscopy 2019
Source of ASGE risk stratification algorithm (low, intermediate, high risk)
PMCID PMC8594622
Tokyo Guidelines 2018 — Antimicrobial Therapy for Acute Cholangitis and Cholecystitis
Gomi H, Solomkin JS, Schlossberg D, et al.
Journal of Hepato-Biliary-Pancreatic Sciences 2018
Severity grading (Grade I, II, III) and timing of biliary drainage
PMID 29090866
Cochrane Review — NSAIDs for Biliary Colic
Fraquelli M, Casazza G, Conte D, Colli A.
Cochrane Database of Systematic Reviews 2016
NNT approximately 3, non-inferior to opioids
Cochrane Review — EUS Versus MRCP for Common Bile Duct Stones
Giljaca V, Gurusamy KS, Takwoingi Y, et al.
Cochrane Database of Systematic Reviews 2015
Equivalent accuracy; EUS advantage for small stones
Management of Gallstone Pancreatitis — JAMA Surgery 2024
McDermott J, Kao LS, Keeley JA, Nahmias J, de Virgilio C.
JAMA Surgery 2024
Review of evidence for timing of cholecystectomy and ERCP
One- and Two-Stage Approaches to Common Duct Stones
Smith SM, Kelley JK, Zambito GM, Banks-Venegoni AL.
The American Surgeon 2025
Single-stage approach associated with shorter stays and decreased morbidity
Management of Choledocholithiasis in the Elderly
Berndtson AE, Costantini TW, Smith AM, et al.
Surgery 2022
Same-admission cholecystectomy as standard of care, PMID 35989133
GRACE-2 Guidelines — Low-Risk Recurrent Abdominal Pain in the ED
Broder JS, Oliveira J E Silva L, Bellolio F, et al.
Academic Emergency Medicine 2022
Risk stratification in ED setting
EUS Versus MRCP for Intermediate Likelihood Choledocholithiasis — RCT
Jagtap N, Kumar JK, Chavan R, et al.
Gut 2022
PMID 35144973
Cardiac Complications from Biliary Disease — Cholecardia Syndrome Review
Li Y, Li J, Leng A, Zhang G, Qu J.
Pharmacological Research 2024
PMID 38000562
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.